Ionis Pharmaceuticals to Host R&D Day

- Webcast on Wednesday, July 13 at 8:30 a.m. ET at www.ionispharma.com

News provided by

Jun 22, 2016, 12:27 ET

CARLSBAD, Calif., June 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that management will host an R&D Day on Wednesday, July 13 at 8:00 a.m. Eastern Time at The London NYC in New York, NY.

The agenda for the meeting is as follows:

8:00 a.m. – 8:30 a.m. ET – Breakfast
8:30 a.m. – 12:30 p.m. ET – Presentations
12:30 p.m. – 1:00 p.m. ET – Networking luncheon

In addition to presentations from the Management team, there will be presentations from leading experts in FCS, SMA and TTR amyloidosis:

Familial Chylomicronemia Syndrome (FCS): Dr. Ira Golberg, Professor of Endocrinology, Department of Medicine NYU Langone Medical Center and Director, Division of Endocrinology; and Dr. Daniel Gaudet, Associate Professor of Medicine and Director of the Community Genomic Medicine Center, Department of Medicine, Université de Montréal and Scientific Director and Strategic Development Officer of BioBank, Genome Quebec's Technological Centers
Spinal Muscular Atrophy (SMA): Dr. Darryl De Vivo, Sidney Carter Professor of Neurology and Pediatrics, Department of Neurology, Columbia University Medical Center
Transthyretin (TTR) Amyloidosis: Dr. Morie Gertz, Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Internal Medicine Mayo Clinic in Rochester, Minnesota

To register to attend the event or listen to the webcast, please visit the "Investors & Media" page at www.ionispharma.com, enter your information and make the appropriate selection from the dropdown menu.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website. A replay of the presentation will be available on the website within 48 hours and will be archived for a limited time.

ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy; IONIS-TTR_Rx, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.

IONIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Ionis Pharmaceuticals' business and the therapeutic and commercial potential of Ionis' technologies and products in development, including nusinersen, IONIS-TTR_Rx and volanesorsen. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2015, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.

Logo - http://photos.prnewswire.com/prnh/20151221/317736LOGO

SOURCE Ionis Pharmaceuticals, Inc.